Nelson D L, Kurman C C
Immunophysiology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Proc Soc Exp Biol Med. 1994 Jul;206(3):309-11. doi: 10.3181/00379727-206-43765.
The high-affinity interleukin-2 receptor (IL-2R) is a multichain receptor with at least three IL-2 binding chains: IL-2R alpha (55 kDa) bound by the monoclonal antibody anti-Tac, IL-2R beta (75 kDa) and Il-2R gamma (64 kDa). The IL-2R alpha also exists as a naturally occurring soluble molecule (sIL-2R alpha). We target the IL-2R for immune intervention since resting normal cells do not express the high-affinity IL-2R, whereas this receptor is on some cells in certain lymphoid neoplasias, select autoimmune disorders, and in individuals rejecting organ allografts. Treatments have included unmodified murine anti-Tac and radioisotopes conjugated to murine anti-Tac. Our emerging understanding of the IL-2R system continues to open possibilities for more specific immune intervention.
高亲和力白细胞介素-2受体（IL-2R）是一种多链受体，至少有三条IL-2结合链：可被抗Tac单克隆抗体结合的IL-2Rα（55 kDa）、IL-2Rβ（75 kDa）和IL-2Rγ（64 kDa）。IL-2Rα也以天然存在的可溶性分子（sIL-2Rα）形式存在。我们将IL-2R作为免疫干预的靶点，因为静息的正常细胞不表达高亲和力IL-2R，而在某些淋巴样肿瘤、特定自身免疫性疾病的一些细胞以及正在排斥器官移植的个体中，该受体是存在的。治疗方法包括未修饰的鼠抗Tac和与鼠抗Tac偶联的放射性同位素。我们对IL-2R系统不断深入的了解继续为更特异性的免疫干预带来可能性。
